Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas R Fleming

Showing results (61-70 of 109) with videos related to

Pageof 11
Sort By:
Statistics in Medicine|February 13, 2024
Methods for the estimation of direct and indirect vaccination effects by combining data from individual- and cluster-randomized trialsRui Wang, Mengqi Cen, Yunda Huang, et al.
Clinical Trials (London, England)|September 2, 2022
Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trialBrett S Hanscom, Deborah J Donnell, Thomas R Fleming, et al.
American Journal of Respiratory and Critical Care Medicine|April 17, 2012
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
Biomedicines|October 26, 2024
The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral SclerosisBruce D Forrest, Namita A Goyal, Thomas R Fleming, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
The European Respiratory Journal|August 29, 2024
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertensionJason Weatherald, Thomas R Fleming, Martin R Wilkins, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
American Heart Journal|April 29, 2008
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005Kevin Jackson, Bernard J Gersh, Norman Stockbridge, et al.
JACC. Heart Failure|June 26, 2026
Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure CollaboratoryVanessa Blumer, Janet T Wittes, Jordan E Pomeroy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled TrialJon T Giles, Naveed Sattar, Sherine Gabriel, et al.
Pageof 11

Showing results (61-70 of 109) with videos related to

Sort By:
Pageof 11
Statistics in Medicine|February 13, 2024
Methods for the estimation of direct and indirect vaccination effects by combining data from individual- and cluster-randomized trialsRui Wang, Mengqi Cen, Yunda Huang, et al.
Clinical Trials (London, England)|September 2, 2022
Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trialBrett S Hanscom, Deborah J Donnell, Thomas R Fleming, et al.
American Journal of Respiratory and Critical Care Medicine|April 17, 2012
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
Biomedicines|October 26, 2024
The Effectiveness of NP001 on the Long-Term Survival of Patients with Amyotrophic Lateral SclerosisBruce D Forrest, Namita A Goyal, Thomas R Fleming, et al.
Statistics in Biopharmaceutical Research|May 26, 2025
Monitoring overall survival in pivotal trials in indolent cancersThomas R Fleming, Lisa V Hampson, Bharani Bharani-Dharan, et al.
The European Respiratory Journal|August 29, 2024
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertensionJason Weatherald, Thomas R Fleming, Martin R Wilkins, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
American Heart Journal|April 29, 2008
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005Kevin Jackson, Bernard J Gersh, Norman Stockbridge, et al.
JACC. Heart Failure|June 26, 2026
Select Contemporary Statistical Concepts in Heart Failure Clinical Trials: Insights From the Heart Failure CollaboratoryVanessa Blumer, Janet T Wittes, Jordan E Pomeroy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 31, 2019
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled TrialJon T Giles, Naveed Sattar, Sherine Gabriel, et al.
Pageof 11